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Abstract
Background: Disease relapse remains common following treatment of acute myeloid leukemia (AML) and is due to
chemoresistance of leukemia cells with disease repopulating potential. To date, attempts to define the characteristics of
in vivo resistant blasts have focused on comparisons between leukemic cells at presentation and relapse. However,
further treatment responses are often seen following relapse, suggesting that most blasts remain chemosensitive. We
sought to characterise in vivo chemoresistant blasts by studying the transcriptional and genetic features of blasts from
before and shortly after induction chemotherapy using paired samples from six patients with primary refractory AML.
Methods: Leukemic blasts were isolated by fluorescence-activated cell sorting. Fluorescence in situ hybridization (FISH),
targeted genetic sequencing and detailed immunophenotypic analysis were used to confirm that sorted cells were
leukemic. Sorted blasts were subjected to RNA sequencing. Lentiviral vectors expressing short hairpin RNAs were used
to assess the effect of FOXM1 knockdown on colony forming capacity, proliferative capacity and apoptosis in cell lines,
primary AML cells and CD34+ cells from healthy donors.
Results: Molecular genetic analysis revealed early clonal selection occurring after induction chemotherapy.
Immunophenotypic characterisation found leukemia-associated immunophenotypes in all cases that persisted
following treatment. Despite the genetic heterogeneity of the leukemias studied, transcriptional analysis found
concerted changes in gene expression in resistant blasts. Remarkably, the gene expression signature
suggested that post-chemotherapy blasts were more proliferative than those at presentation. Resistant blasts
also appeared less differentiated and expressed leukemia stem cell (LSC) maintenance genes. However, the
proportion of immunophenotypically defined LSCs appeared to decrease following treatment, with
implications for the targeting of these cells on the basis of cell surface antigen expression. The refractory
gene signature was highly enriched with targets of the transcription factor FOXM1. shRNA knockdown
experiments demonstrated that the viability of primary AML cells, but not normal CD34+ cells, depended on
FOXM1 expression.
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Conclusions: We found that chemorefractory blasts from leukemias with varied genetic backgrounds expressed a
common transcriptional program. In contrast to the notion that LSC quiescence confers resistance to chemotherapy
we find that refractory blasts are both actively proliferating and enriched with LSC maintenance genes. Using primary
patient material from a relevant clinical context we also provide further support for the role of FOXM1 in
chemotherapy resistance, proliferation and stem cell function in AML.
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Background
The greatest challenge in the management of acute mye-
loid leukemia (AML) is disease relapse which is due to
chemoresistance of leukemia cells with disease repopu-
lating potential. Previous studies have sought to identify
in vivo resistance mechanisms by comparing blasts from
presentation and relapse [1, 2]. However, most cases of
relapsed AML remain chemoresponsive [3], indicating
continued blast cell chemosensitivity, even though they
are derived from an upstream chemoresistant leukemic
stem or progenitor cell. Indeed, the genetic and tran-
scriptional features of surviving leukemia cells shortly
after completion of induction chemotherapy have yet to
be defined. One prevalent hypothesis is that quiescence
enables leukemic stem and progenitor cells (LSCs) to
evade chemotherapy [4]. However, the evidence that
LSCs are indeed quiescent is indirect and contradictory.
In certain leukemia models, the LSC compartment may
be both large and actively proliferating [5, 6]. Related to
this, it is unclear how quiescence could account for pri-
mary refractory disease where a significant proportion of
blasts survive and proliferate.
To identify features characteristic of chemoresistant
AML cells we developed a protocol to study primary re-
fractory disease, thereby facilitating comparison in the
same patient of the transcriptome and mutational status
of AML blast cells at presentation with those recovered
immediately upon induction failure. In particular, we
found that chemorefractory blasts from leukemias with
varied genetic backgrounds expressed a common tran-
scriptional program, signifying that these cells were
more proliferative and less well differentiated. In con-
trast to the notion that LSC quiescence confers resist-
ance to chemotherapy, we found that refractory blasts
are both actively proliferating and enriched for expres-
sion of a LSC maintenance gene signature. In addition,
we found that chemorefractory AML blast cells exhibit
higher expression of genes bound by the Forkhead factor
FOXM1. FOXM1 expression predicts for adverse out-
come in a range of cancers [7, 8] and is highly expressed
in AML where it is required for proliferation, in keeping
with its binding to cell cycle gene homology regions
(CHR) via its interaction with the MuvB complex [9–
11]. Using primary patient material we provide further
support for an important role for FOXM1 in AML.
Methods
Primary AML samples and cell lines
Primary human AML and normal mobilised peripheral
blood samples were from the Manchester Cancer Re-
search Centre Tissue Biobank (approved by the South
Manchester Research Ethics Committee). Their use was
authorized by the Tissue Biobank’s scientific sub-
committee, with the informed consent of donors. THP1,
K562, HL60 and OCI-AML3 cells were acquired from
DMSZ (Braunschweig, Germany).
Cell culture and colony-forming cell assays
Cell lines were cultured in RPMI 1640 with 10% fetal bovine
serum (FBS; Sigma Aldrich, St. Louis, MO) and 50U/ml
penicillin-streptomycin (Thermo Fisher Scientific, Waltham,
MA). Primary AML samples used for FOXM1 knockdown
experiments were expanded on a monolayer of murine MS-
5 stromal cells prior to cryopreservation. Cells were thawed 7
days prior to transduction, recovered on MS-5 monolayers,
then cultured in α-MEM medium (Thermo Fisher Scientific)
supplemented with 12.5% heat-inactivated FBS, 12.5% heat-
inactivated horse serum, 2mML-glutamine, 57.2 μM β-
mercaptoethanol, 1 μM hydrocortisone (Sigma Aldrich) and
IL-3, G-CSF and TPO (all at 20 ng/ml; Peprotech, Rocky
Hill, NJ). Normal CD34+ cells were cultured in α-MEM
medium (Thermo Fisher Scientific) supplemented with
12.5% heat-inactivated FBS, 12.5% heat-inactivated horse
serum, 2mML-glutamine, 57.2 μM β-mercaptoethanol,
1 μM hydrocortisone (Sigma Aldrich), 1 μM StemRegenin 1
(Stem Cell Technologies, Vancouver, Canada) and SCF,
FLT3L and TPO (all at 50 ng/ml; Peprotech).
Colony-forming cell (CFC) assays were performed at a
density of 107/ml in human methylcellulose medium
(H4320, Stem Cell Technologies) with 3 μg/mL puro-
mycin (Sigma Aldrich) and the appropriate combination
of cytokines (as detailed above). Proliferation assays were
performed at a cell density of 25 × 103/ml in the appro-
priate medium with 3 μg/ml puromycin. Live cells were
enumerated by analysing 100 μl of cell suspension using
an Attune™ NxT Flow Cytometer (Thermo Fisher
Scientific).
Flow cytometry
Flow cytometry was performed using an LSR II flow cyt-
ometer (BD Biosciences, Franklin Lakes, NJ). FlowJo
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v10.6.1 (BD Biosciences) was used to analyze data. The
antibody panel (Table S1) was adapted from Freeman
et al. [12] to allow blast gating and identification of
leukemia associated immunophenotypes (LAIPs;
Figs. 1A-B, S1A-B and S2A). CD3 was added to Tube 1
for isolation of T cells to provide germ line DNA for tar-
geted sequencing. Blasts and T-cells were flow sorted
using a FACSAria™ III (BD Biosciences). CD38 expres-
sion cut-offs for identifying LSCs and progenitors were
defined using the upper limit of the red cell fraction
(CD38low) and the median of the red cell fraction
(CD38−).
For cell cycle analysis sorted leukemic blasts or drug-
treated primary AML cells were suspended in ice-cold
70% methanol in H2O and fixed at − 20 °C overnight.
Cells were then washed twice in PBS, suspended in pro-
pidium iodide staining solution (20 μg/ml Propidium
Iodide (Sigma Aldrich) and 500 μg/ml RNAse (Sigma Al-
drich) in PBS) and incubated for 30 min at 37 °C. Sam-
ples were then analysed using a BD LSRII flow
cytometer (BD Biosciences). An Annexin V Apoptosis
Detection Kit (Thermo Fisher Scientific) was used to
stain transduced cells 4 days after puromycin selection
according to the manufacturer’s protocol. Samples were
Fig. 1 A Representative flow cytometry scatter plots show gating strategy for leukemic blast cell sorting. BB numbers indicate Biobank identifier.
B Flow cytometry scatter plots showing the highest frequency leukemia associated immunophenotypes (LAIPs) identified in the indicated primary
AML samples using a difference-from-normal gating strategy
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analysed using a BD LSRII flow cytometer (BD
Biosciences).
Cell viability assays
5 × 103 cells were plated in each well of a 96-well plate
with media containing a serial dilution of RCM-1 (Cam-
bridge Bioscience) or Thiostrepton (Cambridge Bio-
science). Plates were incubated for 96 h at 37 °C. 20 μl of
140 μg/mL resazurin (Sigma Aldrich) was added to each
well. Plates were then incubated for a further 4 h and
read using a POLARstar Omega plate reader (BMG Lab-
tech, Aylesbury, UK).
Fluorescence in situ hybridization (FISH)
Where numbers permitted, ~ 10,000 sorted blasts were
fixed in methanol:acetic acid (3:1), slide mounted and
subjected to FISH. Monosomy 7 provided a target in 3/6
leukemias and was detected using a Vysis D7S522/CEP7
FISH probe kit (Abbott Molecular, Abbott Park, IL).
Targeted DNA sequencing with TruSight myeloid panel
DNA was extracted from sorted blast and T-cell popula-
tions using a QIAamp DNA Micro Kit (Qiagen, Man-
chester, UK). Where cell numbers were < 5 × 104 DNA
was amplified using a REPLI-g mini kit (Qiagen). Gen-
omic DNA was then subjected to targeted next gener-
ation sequencing (NGS) using a NextSeq 500 sequencer
(Illumina, San Diego, CA). The TruSight Myeloid Se-
quencing Panel (Illumina) targets 54 genes recurrently
mutated in myeloid neoplasms using a proprietary mul-
tiplexed oligonucleotide pool covering each region of
interest. Libraries were generated according to the man-
ufacturer’s protocol. Briefly, genomic DNA was quanti-
fied using a Qubit DNA BR assay kit (Life Technologies,
Carlsbad, CA) and diluted to 50 ng in 96 well plates. Oli-
gonucleotides were hybridized to regions of interest,
followed by an extension-ligation reaction and PCR
amplification, incorporating unique combinations of i5/
i7 index sequences to permit multiplexing up to 96 sam-
ples per sequencing run. Successful amplification was
confirmed using a DNA 1000 kit and the 2100 Bioanaly-
zer system (Agilent Technologies, CA). Libraries were
purified using AMPure magnetic beads (Agencourt,
Brea, CA) and bead-normalized according to the Tru-
Sight protocol. Libraries were pooled (5 μL per library,
96 per pool) and quantified by PCR to determine molar-
ity for loading onto the NextSeq flow cell. Paired end
(150 bp) sequencing was performed on the NextSeq 500
sequencer (Illumina) with 96 samples multiplexed on a
single NextSeq 500 High Output run (300 cycles).
Data analysis was performed within Illumina’s online
BaseSpace genomics analysis platform. FASTQ files were
aligned to human genome reference GRCh37/hg19 by
the TruSeq Amplicon App (v2.0; Illumina) using a
banded Smith-Waterman algorithm. Variant calling was
performed by Somatic Variant Caller (v4.0.13.1; Illu-
mina) using default parameters. The resulting gVCF files
were uploaded to Variant Studio (v2.2.3; Illumina) for
downstream filtering and annotation (from RefSeq data-
base) of high confidence variants. Variant allele fre-
quency was calculated as the fraction of mutated reads
versus total number of reads covering that base. Muta-
tions were considered present if they had a variant allele
frequency > 10%, a total depth > 500, were absent from
germline (T-cells) and were annotated in the COSMIC
database [13].
RNA extraction, sequencing and data analysis
Total RNA was extracted from 103 to 105 sorted blasts
using QIAshredder spin columns and a RNeasy® Plus
Micro kit (Qiagen). Prior to sequencing RNA integrity
was checked using a 2100 Bioanalyzer (Agilent Tech-
nologies, Santa Clara, CA). Total RNA yield from the
sorted populations ranged from 3.5-475 ng. To ensure
consistency the sample with the lowest yield was used to
define the input (3.5 ng) for amplification of all samples.
Amplification was performed using a SMARTer
Stranded Total RNA-Seq Pico input kit (Clontech,
Mountain View, CA). Sequencing was performed using a
NextSeq desktop sequencing system (Illumina). A single
run (400M reads) of 151 bp paired-end sequencing pro-
duced a mean of 31.4M reads per sample (range 29.3–
33.5M). Reads were aligned to the human genome
(hg38) using STAR v2.4.2a [14]. DEseq2 was used to cal-
culate FPKM (fragments per kilobase of transcript per
million mapped reads) values for each transcript [15].
Principal component analysis was performed using
ggplot2 [16] and heatmaps were generated using R. Gene
ontology analysis was performed using the DAVID Bio-
informatics Resource 6.7 [17]. Gene set enrichment ana-
lyses were performed using GSEA v4.0.1 software [18].
Expressed protein coding genes were ranked using a
signal-to-noise metric. Potential transcriptional regula-
tors were identified by screening genes upregulated in
post-chemotherapy blasts with consensus transcription
factor targets using Enrichr [19, 20]. FOXM1 transcrip-
tional targets were from ChIPseq experiments performed
by Chen et al. [21].
Quantitative PCR
RNA was extracted from primary AML, normal CD34+
cells and cell lines using an RNeasy® Plus Micro kit (Qia-
gen). cDNA was generated using a High Capacity cDNA
Reverse Transcription Kit (Thermo Fisher Scientific).
qPCR reactions were performed in MicroAmp® optical
384-well reaction plates and analysed using a QuantStu-
dio® 5 PCR system (Applied Biosystems). Reactions were
performed in triplicate and included primers for β-Actin
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(ACTB) as a housekeeping gene. Primers were designed
using the Universal Probe Library (UPL) Assay Design
Center (Roche, Basel, Switzerland) and purchased from
Integrated DNA Technologies (IDT, Coralville, IA). Raw
fluorescence data was converted to Ct values using the
Thermo Fisher Cloud facility (Waltham, MA) and nor-
malised to ACTB. Primers were (i) ACTB (F) ATTG
GCAATGAGCGGTTC, (R) GGATGCCACAGGACTC
CAT, UPL probe #11 and (ii) FOXM1 (F) AGAAACGG
GAGACCTGTGC, (R) CCACTGGATGTTGGATAG
GC, UPL probe #74.
CD34 enrichment
CD34+ cells from healthy donor mobilised peripheral
blood were enriched by magnetic-activated cell sorting
(MACS). Briefly, cryopreserved samples were thawed
and dead cells removed with a Dead Cell Removal Kit
(Miltenyi Biotec, Bergisch Gladbach, Germany). Double
CD34+ enrichment was then performed using UltraPure
CD34 MicroBeads (Miltenyi Biotec), according to the
manufacturer’s protocol, resulting in CD34+ cell purity
> 95%. Cells were maintained in culture for 5 days prior
to transduction to allow cell recovery.
Lentiviral vector construction and transduction
pLKO.1-puro (Sigma Aldrich) was used to express short
hairpin RNAs (shRNAs) targeting human FOXM1
(FOXM1 KD#1: 5′-GCCCAACAGGAGUCUAAUCAA-
3′; FOXM1 KD#2: 5′-GCCAAUCGUUCUCUGACA-
GAA-3′). Oligonucleotides (IDT) were annealed through
incubation at 98 °C for 5 min, and cooling to room
temperature. The vector was digested with AgeI and
EcoRI (New England Biolabs, Ipswich, MA) and ligated
to the annealed oligonucleotides. Cloning was confirmed
using Sanger sequencing. A pLKO.1-puro vector con-
taining a non-targeting oligonucleotide (SHC002) was











Lentiviral particles were generated through
polyethylenimine-mediated transfection of HEK293T
cells. AML or normal human CD34+ cells were twice
cultured overnight in fresh viral supernatant supple-
mented with the relevant cytokines (as above), polybrene
(8 μg/mL; Merck Group, Darmstadt, Germany), and
DEAE-Dextran (4 μg/mL; Sigma Aldrich). Cells were
subsequently transferred into fresh media (as above)
with 3 μg/ml puromycin and cultured for 48 h prior to
analysis. Cells were maintained in puromycin in all sub-
sequent assays.
Results
To characterise the genetic and transcriptional features
of chemorefractory primary AML samples, we per-
formed molecular genetic and RNA sequencing analyses
of flow sorted, paired blast samples collected from six
patients at presentation and following one (n = 5) or two
(n = 1) courses of induction chemotherapy (Table 1).
Blasts were flow sorted according to either a CD45lo-
w/intCD34+ (n = 5) or, in a case which lacked CD34 ex-
pression, CD45low/intCD117+ (n = 1) immunophenotype
(Fig. 1A and S1A-B). The leukemic origin of sorted blast
populations was confirmed using fluorescence in situ
hybridization (FISH) where suitable chromosomal
markers permitted (Table 2) and targeted sequencing of
54 genes recurrently mutated in myeloid neoplasms (Ta-
bles 3 and S2). Over and above flow sorting based on
the above mentioned immunophenotypes, samples were
also analysed using an extended flow panel to identify
leukemia-associated immunophenotypes (LAIPs; Figs.
1B, S2A and Table 3) to provide additional confirmation
that post-chemotherapy cells were leukemic and not re-
generating normal progenitors [12]. In keeping with the
concept that different genetic sub-clones exhibit differ-
ent levels of chemosensitivity, molecular genetic analysis
revealed the presence of early clonal selection following
the first cycle of chemotherapy, with the emergence of
new subclones (patients 64, 285, and 349), the loss of
pre-treatment subclones (patients 285 and 494) or a re-
duction in size of the dominant clone (patients 64 and
285; Tables 3 and S2). The identified LAIPs were ob-
served both before and after chemotherapy in each case,
although the change in percentage of BM cells positive
for each LAIP did vary widely (Table 3, Figs. 1B and
S2A). There was no consistent or statistically significant
change in expression of cell surface markers between
pre- and post-chemotherapy samples (Fig. S2B). Thus,
even in patients proving to be refractory to their first
cycle of chemotherapy there was nevertheless often evi-
dence of chemotherapy-induced clonal selection.
We next performed RNA sequencing of the paired
pre- and post-chemotherapy CD45low/intCD34+ or
CD45low/intCD117+ sorted blast cell populations. As ex-
pected, given the genetic heterogeneity of the analysed
samples, principal component analysis (PCA) of 7123
expressed protein-coding genes revealed significant tran-
scriptional differences between the six leukemias (Fig. 2A;
Table S3). By contrast, post-chemotherapy samples were
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Sex WHO (2016) WCC Karyotypeb Sample Inductionc Response Sample Blast
%e
Days
since start of Rx
Outcome
64 40–59 M AML with
inv.(3)





BM 5% 33 Relapsed and
died following
HSCTf
121 16–39 F AML with
inv.(3)










12.6 Monosomal PB DA (90)
FLAG-IDA4
Refractory BM 12% 62d Relapsed and
died following
HSCTf




3.9 Normal PB DA Refractory BM 30% 32 Induction
failure; died
349 40–59 M AML, not
otherwise
specified






494 60–79 M AML, not
otherwise
specified
30.2 Monosomal BM DA Refractory BM 58% 32 Induction
failure; died
aBiobank identifier
bSee Table 2 for details
cInduction regimes: ADE Cytarabine, Daunorubicin, Etoposide; GO Gemtuzumab ozogamycin; DA Daunorubicin (standard dose 60 mg/m2, patient 205 received 90
mg/m2 as part of a clinical trial), Cytarabine; FLAG-IDA Fludarabine, Cytarabine, G-CSF, Idarubicin
dThe post treatment sample for patient 205 was collected after a second cycle of chemotherapy. All other post-treatment samples were collected following
induction chemotherapy
eBlast percentage following treatment as determined by clinical service flow cytometry (FC). FC not performed for sample 64 2 M; results are shown for trephine
histopathology (5%)
fHSCT performed in the presence of persistent cytogenetic abnormality but morphological remission
WCC, white cell count (× 109/l); PB, peripheral blood; BM, bone marrow; HSCT, hematopoietic stem cell transplantation; Rx, treatment
Table 2 Fluorescence in situ hybridization (FISH) on sorted blasts
Biobank
number





64 46, XY, inv.(3)(q21q26), del(7)(q22) [10] Failed Insufficient material NA






205 44, XX, add(3)(p25), −5, −7[12] 61/100 1G1O 39/
100 1G




494 45 ~ 49, XY, −4, −5, −7, del(9)(q?22),? der(15;17) (q10;q10), + 21,
del(22)(q13), + 2 ~ 5mar[cp10]




Where sufficient cells were available, FISH was used to confirm clonality of sorted blast populations. Samples 285 and 349 had normal cytogenetics and no target
for FISH. Samples 121, 205 and 494 had monosomy 7 which was detected using two probes: CEP7 (green probe targeting the centromere, 7p11.1-q11.1) and
D7S522 (orange probe targeting 7q31). 1G1O, 1 green and 1 orange signal per cell; 1G, 1 green signal per cell
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generally quite similar to pre-chemotherapy samples
from the same leukemia. The sole exception was the pair
of samples from patient 285, the case with the most sub-
stantial chemotherapy-induced clonal evolution (Fig. 2A;
Table 3). To search for consistent changes in the tran-
scriptome of pre- and post-chemotherapy samples, we
performed differential gene expression analysis. We
identified 150 and 42 genes as significantly up or down
regulated respectively (p < 0.05 by paired t-test, fold
change > 1.5 or < 0.67; Fig. 2B and Table S4). Among
significantly up regulated genes there was enrichment
for Gene Ontology Biological Process terms “cell div-
ision” (GO:0051301; P = 10− 21) and “mitotic nuclear div-
ision” (GO:0007067; P = 10− 13). There was no significant
enrichment for any term among significantly down regu-
lated genes [17]. To characterise the transcriptional
changes in post-chemotherapy versus pre-chemotherapy
AML blasts in greater depth and to detect co-ordinate
changes in expression of a priori defined gene sets, we
also performed pre-ranked Gene Set Enrichment Ana-
lysis (GSEA) using a signal-to-noise ranking metric [18].
Evaluation of the pattern of expression of the Molecular
Signatures Database Hallmark Gene Set collection, each
of which conveys a specific biological state or process
and displays coherent expression [22], demonstrated
strong up regulation of “E2F target” genes, “G2M cell
cycle checkpoint” genes and “MYC target” genes in post-
versus pre-chemotherapy AML blast cells (Fig. 2C). In
addition, there was down regulation of “inflammatory re-
sponse” genes, and genes regulating “TNFA signalling
via NFKB”, “Interferon gamma response” and “Interferon
alpha response” (Fig. 2C). Given that these latter gene
sets are characteristic of terminally differentiated mye-
loid cells we performed similar GSEA analyses using sets
of genes preferentially expressed in normal human
monocytes and neutrophils (Table S4) [23, 24] and ob-
served that these gene sets were also strongly down reg-
ulated in post- versus pre-chemotherapy AML blast cells
(Fig. 2C). Together these data indicate that AML blast
cells surviving chemotherapy are more proliferative and
less well differentiated than those at presentation. One
sample from patient 121 had sufficient residual sorted
blasts before and after chemotherapy to permit cell
cycle analysis: propidium iodide staining confirmed a
remarkable 4-fold higher percentage of blast cells in
SG2M in post- versus pre-chemotherapy AML blast
cells (Fig. 2D).
While we observed these transcriptional features in pri-
mary human chemorefractory AML cases, they are neverthe-
less reminiscent of our prior findings in a murine model of
human MLL-translocated AML where we found the LSC
compartment to be more proliferative and less well
Table 3 Summary of mutation analyses of sorted blast populations
Clinical details Molecular Genetics Leukemia-associated
immunophenotype (LAIP)

































































































































Summary of Trusight Myeloid Sequencing Panel targeted next generation sequencing (NextSeq 500 System, Illumina) of sorted blast populations (see Table S2 for
complete data). Also shown is the frequency of the indicated leukemia associated immunophenotype (LAIP) for each sample. C, chemotherapy
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Fig. 2 A Principal component analysis (PCA). B Heatmap shows differentially expressed genes (150 upregulated and 42 downregulated; paired t-
test < 0.05, mean fold change > 1.5 or < 0.67). C Gene set enrichment analysis plots. NES, normalised enrichment score; FDR, false discovery rate.
D Flow cytometry histograms show propidium iodide staining of flow sorted AML blasts pre- and post-chemotherapy from patient BB121
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differentiated than downstream cells [6, 25]. Indeed
cross-species comparison of the gene set associated
with LSC maintenance in murine MLL-AF9 AML
cells showed significantly higher expression in post-
versus pre-chemotherapy human AML cells, and vice
versa for genes whose expression is anti-correlated
with leukemia stem cell activity (Table S4 and
Fig. 3A). Intriguingly, leading edge analysis of the
genes driving enriched expression of the LSC main-
tenance signature in post- versus pre-chemotherapy
blast cells revealed the presence of MYB, HMGB3
(High Mobility Group Box 3) and CBX5 (Chromo-
box 5) the three genes which, when co-expressed, suf-
fice for Hox/Meis-independent immortalization of
myeloid progenitor cells (Fig. 3A) [6].
Our analysis of LAIPs uncovered an additional unexpected
finding: a consistent reduction in the percentage of immuno-
phenotypic LSCs (CD34+CD38−) following chemotherapy.
Consistent with reports that LSC frequencies at presentation
predict for poor survival [26], the frequency of immunophe-
notypic LSCs was typically high at presentation (median
9.9%, range 0.36–47.3%; n = 5). Following chemotherapy,
among surviving AML cells, there was a significant reduction
in the proportion of cells with either an LSC immunopheno-
type (CD34+CD38−) or a progenitor immunophenotype
(Figs. 3B-C). The seeming disconnect between a relative in-
crease in expression of genes associated with LSC mainten-
ance and a reduction in numbers of immunophenotypically-
defined LSCs is striking but may be explained by the imper-
fect ability of cell surface markers such as CD34 and CD38
to define functional LSC potential. Related to this, there is
plentiful evidence that LSCs may be aberrantly self-renewing
downstream progenitor cells expressing cell surface markers
more characteristic of mature myeloid populations [27].
Next, to identify transcription factor regulators of the
refractory blast gene expression signature, which may
serve as candidate therapeutic targets, we performed an
in silico analysis using Enrichr [7, 28], a bioinformatics
resource which facilitates analysis of experimentally de-
rived gene sets. Among the 150 genes upregulated in re-
fractory AML blast cells (Table S4), the most significant
enrichment among the 92 sets of transcription factor
binding sites interrogated was for genes bound by the
Forkhead transcription factor FOXM1 (Fig. 3D), whose
expression is known to predict for adverse outcomes in
cancer [7, 8]. Thus, among genes up regulated in post-
versus pre-chemotherapy AML blasts there is significant
enrichment for those known to be direct targets of
FOXM1 binding. Consistent with this, expression of
FOXM1 increased markedly following chemotherapy in
five of six cases (Fig. 3E).
To further assess the contribution of FOXM1 to the
refractory blast gene signature we performed correlation
analyses between the absolute expression values (FPKM)
of FOXM1 and the genes significantly upregulated in re-
fractory blasts (Table S5). We hypothesised that genes
directly controlled by FOXM1 were likely to exhibit
highly correlated gene expression patterns across all 12
pre- and post-chemotherapy samples tested. 82/150
genes were significantly, positively correlated with
FOXM1 expression (Pearson R > 0.5, p < 0.05; Fig. 3F).
In keeping with the known binding of FOXM1 to DNA
sequences termed cell cycle gene homology regions
(CHR) via its interaction with the MuvB complex [9]
several of the most highly correlated genes were regula-
tors or markers of cell cycle progression (CCNB2,
MKI67, TPX2 & BIRC5), suggesting that FOXM1 may
serve to sustain post-chemotherapy AML cell prolifera-
tion (Figs. 3E-F and S3A). Of note, the one leukemia
that did not exhibit increased FOXM1 expression follow-
ing chemotherapy (494) had the highest baseline expres-
sion of refractory-associated genes, including FOXM1
and associated cell cycle genes (Figs. 2B, Fig. 3G and
S3B). Patient 494 also had the highest blast count at
presentation and the most aggressive clinical course
(remaining refractory to salvage chemotherapy), indicat-
ing highly aggressive, proliferative disease (Table 1).
Having identified abundant FOXM1 targets among the
150 genes upregulated in refractory blasts we next
sought to assess the expression of all FOXM1 targets in
pre- versus post-chemotherapy blasts. We made use of a
ChIP sequencing dataset generated from the human
osteosarcoma cell line U2OS [21]. In published datasets,
FOXM1 predominantly binds the 5’UTR and promoter
regions of target genes [29]. Of the 270 high confidence
FOXM1 targets in U2OS cells, 206 occupied positions ±
1kB from a transcription start site. In GSEA, there was
substantial and highly significant enrichment of genes
bound at the promoter by FOXM1 among genes up reg-
ulated in post-chemotherapy AML blasts (Table S4 and
Fig. 3H). Of note, there was minimal overlap between
the FOXM1 target and LSC maintenance gene sets, with
only PTTG1 (Pituitary Tumor-Transforming Gene 1),
ZADH2 (Zinc Binding Alcohol Dehydrogenase Domain
Containing 2) and DTYMK (Deoxythymidylate Kinase)
found in both sets. This is in keeping with our prior
studies which demonstrated that the LSC maintenance
signature reflects a leukemic self-renewal program pre-
dominantly driven by expression of MYB [6], rather than
merely a signature of cell proliferation.
FOXM1 is more highly expressed in primary human
AML cells than in normal hematopoietic stem and pro-
genitor cells (HSPCs) and is required for their prolifera-
tion [10, 11] and its expression has been linked to
chemoresistance in AML cell lines [30]. Levels of nu-
clear FOXM1 have been correlated with patient treat-
ment response [11], and in murine models of MLL-AF9
induced AML it is required for optimal LSC function
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[31]. To confirm and extend these findings, we studied
the effect of shRNA-induced knockdown in four
FOXM1-expressing human AML cell lines (Fig. S4A-B).
FOXM1 knockdown significantly reduced the capacity of
all cell lines to proliferate in liquid culture and to form
colonies in semi-solid medium (Figs. 4A-C and S4C).
Interestingly, this effect was least pronounced in the
NPM1 mutant cell line (OCI-AML3), consistent with
previous studies suggesting that nuclear export of
FOXM1 by mutant NPM1 contributes to the relative
Fig. 3 A Gene set enrichment analysis (GSEA) plots. NES, normalised enrichment score; FDR, false discovery rate. B Representative flow cytometry scatter plots
show the relative size of the immunophenotypic leukemia stem and progenitor cell populations pre- and post-chemotherapy. CMean±SD relative size of AML
stem and progenitor populations (n =5). Sample 494 was excluded as the blasts lacked CD34 expression at presentation. ** P <0.01, *** P< 0.001 by unpaired t-
test. BB numbers indicate Biobank identifier. D Table shows enrichment of gene sets directly bound by the indicated transcription factors among the 150 genes
upregulated in post-chemotherapy AML blasts. The combined score is the product of the logarithm of the adjusted p-value and the z-score (20). The analysis was
performed using Enrichr (19). E Expression of the indicated genes in pre- and post-chemotherapy flow sorted AML blast populations (n =6). FPKM, fragments per
kilobase of transcript per million mapped reads. * P <0.05 by ratio paired t-test. F Scatter plot shows correlations between absolute expression values (FPKM) for
FOXM1 and the 150 genes significantly upregulated in post-chemotherapy blasts (Table S5; n =12). R represents the Pearson product moment correlation
coefficient. G Bar charts show expression of the indicated genes in all samples. FPKM, fragments per kilobase of transcript per million mapped reads. H GSEA plot
shows significantly enriched expression of FOXM1 target genes in post- versus pre-chemotherapy AML blasts. NES, normalised enrichment score; FDR, false
discovery rate
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chemosensitivity of this leukemia [30]. To determine
whether these findings were due to reduced cell prolifer-
ation or impaired viability we performed cell cycle ana-
lysis and Annexin-V apoptosis assays. Consistent
changes in cell cycle status were not observed following
FOXM1 knockdown (Fig. S4D), whereas cell viability de-
creased significantly in all cell lines (Figs. 4D and S4E-F).
To expand these findings, we performed shRNA-
Fig. 4 A-D AML cell lines were infected with lentivirus targeting FOXM1 for knockdown (KD#1 and KD#2) or a non-targeting control (NTC). Cells were plated
into proliferation or colony-forming cell (CFC) assays after 48 h of puromycin drug selection (i.e. Day 0). Apoptosis assays were performed after four days of
puromycin drug selection. A Bar chart shows mean ± SD (n = 3) cell count on Day 7 of culture in the indicated conditions. Cell counts are shown relative to Day 0.
B Representative images of CFC assays. Bar charts showmean ± SD (n =3) (C) CFC frequencies or (D) cell viability in the indicated conditions for the indicated
cell lines. E-H Primary AML cells (BB104, BB108 & BB160) and normal CD34+ HSPCs from healthy donors (HD1 & HD2, apoptosis assays only) were infected with
lentivirus targeting FOXM1 for knockdown (KD#1 and KD#2) or a non-targeting control (NTC). Cells were plated into proliferation or colony-forming cell (CFC)
assays after 48 h of puromycin drug selection (i.e. Day 0). Apoptosis assays were performed after four days of puromycin drug selection. E Bar chart shows
mean ± SD (n = 3) cell count on Day 7 of culture in the indicated conditions. Cell counts are shown relative to Day 0. F Representative images of CFC assays. Bar
charts showmean ± SD (n = 3) (G) CFC frequencies or (H) cell viability in the indicated conditions for the indicated cells. * P <0.05, ** P <0.01, *** P <0.001 by
one-way ANOVA with Dunnett’s multiple comparison test (A-G) or unpaired t-test (H). BB numbers indicate Biobank identifier
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induced FOXM1 knockdown in three cases of primary
AML with an MLL gene rearrangement which all exhib-
ited high FOXM1 expression (Table S6, Figs. S4A and
S5A). FOXM1 knockdown prevented proliferation in li-
quid culture and abolished colony formation in all pri-
mary cells (Figs. 4E-G and S5B). The reduction in cell
viability was even more pronounced than that observed
in AML cell lines (Figs. 4H and S5C). To assess the po-
tential of FOXM1 as a therapeutic target in AML we de-
termined the effect of FOXM1 knockdown on the
viability of normal CD34+ HSPCs from two healthy do-
nors (Figs. S4A and S5A). Consistent with recent reports
[31], FOXM1 knockdown did not induce apoptosis in
normal HSPCs (Figs. 4H and S5C).
The compounds Thiostrepton and RCM-1 have been
reported to inhibit FOXM1 activity [32, 33]. In contrast
to FOXM1 knockdown, following drug treatment we ob-
served reduced cell growth due to apoptosis in both
AML cells and in normal CD34+ HSPCs at similar IC50s
(Figs. S6A-D). This is likely due to off target effects. For
example, while thiostrepton binds FOXM1 [33] it also
binds the proteasome [34] and the large subunit of the
mitochondrial ribosome [35]. Likewise the mechanism
by which RCM-1 promotes ubiquitination and proteaso-
mal degradation of FOXM1 is unknown [32] and it is
not clear what other proteins are concomitantly targeted
for degradation.
All together these data confirm that by comparison
with normal hematopoietic stem and progenitor cells,
FOXM1 appears selectively required for leukemia cell
proliferation.
Discussion
Transcriptome studies in AML over the last two de-
cades have been helpful in identifying critical genes
and cellular pathways that contribute to
leukemogenesis. However, the practical challenges of
collecting post-chemotherapy material containing suf-
ficient leukemic blasts for analysis have resulted in a
lack of studies comparing paired pre- and post-
chemotherapy samples. Post-chemotherapy bone mar-
row is often hypocellular and the majority of patients
remit after induction chemotherapy. Our prospective
biobanking strategy of collecting bone marrow from
all patients at presentation and after induction has
enabled accumulation of a set of paired pre- and
post-chemotherapy samples from patients with refrac-
tory disease. These samples enabled us to perform de-
tailed genetic and transcriptional characterisation of
the blasts that survived chemotherapy.
Despite significant genetic heterogeneity we found
that chemorefractory primary AML blasts shared
common transcriptional features. Most striking was
the enrichment of genes involved in cell cycle
progression, implying that chemoresistant blasts were
more proliferative than their chemosensitive counter-
parts. This was a remarkable finding given the preva-
lent hypothesis that AML cells survive chemotherapy
because of replicative quiescence. While we cannot
exclude the possibility that blasts in G0 survive
chemotherapy then enter the cell cycle rapidly follow-
ing completion of chemotherapy, this seems unlikely.
If quiescence were a dominant mechanism of resist-
ance but chemotherapy exposure was sufficient to
stimulate widespread cell cycle entry we would expect
to see improved outcomes following extended treat-
ment courses or pulsed maintenance strategies. Whilst
these approaches are effective in acute lymphoblastic
leukemia, where the evidence for LSC quiescence is
more compelling, they have not been effective in
AML [36, 37]. Contrary to previous studies, our data
argue against quiescence as a mechanism of chemore-
sistance, but are concordant with the clinical litera-
ture identifying high presentation blast count as a
predictor of treatment failure [5, 38]. Our data are
also consistent with murine studies where LSCs have
been found to be both actively cycling, frequent and
chemoresistant [5, 6].
TIM3 and CD47 are LSC markers that have generated
considerable interest as potential targets of cellular or
antibody-based immunotherapy [39, 40]. However, we
found that the proportion of immunophenotypically de-
fined LSCs fell following chemotherapy whilst the ex-
pression of stem cell genes increased. Previous studies
have described a similar decoupling of stemness from
immunophenotype in murine models of AML [41].
These findings have implications for the therapeutic tar-
geting of LSCs based on cell surface immunophenotype,
at least if treatment is delivered concomitantly with
chemotherapy. Additional studies are required to con-
firm that the expression of potential targets is stable fol-
lowing chemotherapy exposure. If the cells that actually
survive chemotherapy do not necessarily express puta-
tive LSC markers then their targeting is unlikely to im-
prove patient outcomes.
Our data identifies the Forkhead transcription factor
FOXM1 as both a candidate regulator of the chemor-
efractory gene expression program and also as essen-
tial for AML but not normal HSPC viability, at least
in vitro. FOXM1 has been implicated in all major
hallmarks of cancer and a major meta-analysis of ex-
pression signatures from ~ 18,000 human cancers
identified the FOXM1 regulatory network as a major
predictor of adverse outcome [8, 42]. Nuclear FOXM1
expression predicts treatment failure in intermediate
risk AML and was found to drive proliferation and
clonogenic potential in leukemic cell lines [10, 11].
Constitutive expression also conferred resistance to
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cytarabine in a murine myeloid leukemia model [11].
Our data, derived from primary patient material taken
at clinically relevant time points, support these find-
ings and provide an additional rationale for the thera-
peutic targeting of FOXM1.
A recent study by Sheng et al. demonstrated that FOXM1
was essential for LSC function in MLL-rearranged murine
AML [31]. Whilst we found minimal overlap between
FOXM1 target genes and the LSC maintenance programme,
we cannot rule out indirect regulation. We also lack FOXM1
binding data from AML, which may differ from other cell
types because FOXM1 is able to bind non-consensus se-
quences via co-factors [43]. Sheng et al. found that whilst
FOXM1 promoted LSC quiescence in steady state condi-
tions, conditional FOXM1 knockout prevented leukemic re-
population of murine bone marrow following chemotherapy.
These observations are concordant with our finding that the
blasts repopulating human bone marrow after unsuccessful
treatment express high levels of FOXM1 and it targets. Im-
portantly, our data suggest that the role of FOXM1 in AML
is not limited to cases with MLL-rearrangement, but com-
mon to multiple genetic subtypes.
Conclusions
Our work demonstrates that chemorefractory blasts from
leukemias with varied genetic backgrounds nonetheless ex-
press a common transcriptional signature. Remarkably, we
find that leukemic cells surviving chemotherapy are both
enriched with LSC maintenance genes and are more prolifer-
ative and less well differentiated than those at presentation.
These data suggest that replicative quiescence is not a dom-
inant mechanism of resistance in AML. The refractory blast
gene signature implicates the transcription factor FOXM1
and we provide further support for the role of FOXM1 in
chemotherapy resistance, proliferation and stem cell function
in AML.
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